Bone Biologics CorpBBLG
Price (close)
$0.50
Market cap
$1.4M
P/E
—
Revenue (TTM)
—
Net income
-$2.9M
Dividend yield
—
1-year total return
-76.7%
Net margin
—
Revenue growth
—
Debt / equity
—
What Bone Biologics Corp does.
are a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known
as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific
control over bone regeneration. The NELL-1 technology platform has been licensed exclusively for worldwide applications to us through
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | — | — | — | — | — |
| Net income | -$1.8M | -$1.6M | -$1.5M | -$8.9M | -$4.1M | -$3.1M |
| Free cash flow | — | — | — | — | — | — |
More on BBLG.
- Bone Biologics Corp summary
- Bone Biologics Corp financial statements
- Bone Biologics Corp key metrics
- Bone Biologics Corp health scores and style box
- Bone Biologics Corp earnings
- Bone Biologics Corp dividends
- Bone Biologics Corp valuation
- Bone Biologics Corp ownership and insiders
- Bone Biologics Corp peers
Figures from Bone Biologics Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.